Dicot Pharma outlines Phase 2b trial design for ED drug candidate LIB-01

• Dicot Pharma highlighted new data on its erectile-dysfunction candidate LIB-01 at the SMSNA conference.
• Results were already presented via three abstracts covering how the drug works, early clinical findings, and the planned mid-stage trial.
• Early clinical outcomes indicated meaningful, sustained improvements in erectile function following short dosing, with tolerable safety.
• The company outlined a Phase 2b study built around durable effects, using monthly dosing with multiple dose levels.
• A webcast later today will replay the presentations for investors, with some content delivered in Swedish.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dicot Pharma AB published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.